Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Diaz Castro

Hematology & Oncology Huntsville, AL Medical Doctor

NPI 1558517987 CMS profile 749526

1 Hospital Dr Sw, Huntsville, AL 35801

Open in the dashboard

General payments

$13,910

669 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$61,402 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Jorge Diaz Castro of Huntsville, AL is reported in the CMS Open Payments database as having received $13,910 across 669 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $61,402 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,950 115
2024 General $2,670 101
2023 General $1,759 79
2022 General $1,639 89
2021 General $1,079 36
2020 General $1,289 60
2019 General $2,523 189

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Diaz Castro
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Jorge Diaz Castro were reported at $2,950. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Jorge Diaz Castro Hematology & Oncology median Middle half National median
2019 $2,523 $529 $121–$2,516 $163
2020 $1,289 $339 $82–$2,213 $114
2021 $1,079 $263 $49–$1,965 $132
2022 $1,639 $416 $103–$2,395 $149
2023 $1,759 $542 $125–$2,646 $160
2024 $2,670 $692 $141–$3,008 $164
2025 $2,950 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,249 73 payments
  2. Merck Sharp & Dohme Corporation $854 44 payments
  3. Amgen Inc. $796 25 payments
  4. AstraZeneca Pharmaceuticals LP $763 41 payments
  5. Pfizer Inc. $699 47 payments
  6. E.R. Squibb & Sons, L.L.C. $687 50 payments
  7. Janssen Biotech, Inc. $524 25 payments
  8. Seattle Genetics, Inc. $502 27 payments
  9. BeiGene USA, Inc. $433 10 payments
  10. Welch Allyn $432 1 payment
  11. Other $6,970 326 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,937 658 payments
  2. Long term medical supply or device loan $432 1 payment
  3. Education $270 7 payments
  4. Honoraria $150 1 payment
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $120 2 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $835 43 payments
  2. OPDIVO $513 37 payments
  3. BRUKINSA $509 14 payments
  4. Connex Vital Signs Monitor 6800 $432 1 payment
  5. Blincyto $390 7 payments
  6. KISQALI $327 19 payments
  7. Lenvima $303 20 payments
  8. Vectibix $295 5 payments
  9. TUKYSA $289 18 payments
  10. XTANDI $265 12 payments
  11. Other $12,232 632 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

1,524

Median for Hematology-Oncology: 604

Drug cost

$2,771,464

Median for Hematology-Oncology: $1,306,514

Branded share of claims

36.7%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 29 $485,871
Jakafi Ruxolitinib Phosphate Brand 25 $435,399
Verzenio Abemaciclib Brand 21 $317,360
Nubeqa Darolutamide Brand 22 $291,585
Xtandi Enzalutamide Brand 24 $262,980
Sprycel Dasatinib Brand 12 $220,060
Vizimpro Dacomitinib Brand 12 $184,776
Brukinsa Zanubrutinib Brand 20 $181,493
Promacta Eltrombopag Olamine Brand 11 $150,502
Eliquis Apixaban Brand 180 $131,013

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 200 billing codes

Paid by Medicare

$3,207,569

Of which drugs: $2,814,188

Medicare patients

783

Average age 74

Services billed

152,499

453 women, 330 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Cancer 38%
Chronic kidney disease 36%
Diabetes 35%
Ischemic heart disease 35%
Atrial fibrillation 24%
Depression 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 19 13,000 $578,104
Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg Q5127 Office 23 636 $164,515
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 15 3,700 $137,537
Injection, denosumab, 1 mg J0897 Office 50 5,520 $113,272
Injection, ferric derisomaltose, 10 mg J1437 Office 29 4,000 $62,812
Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 Office 15 15,480 $35,790
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 Office 25 62 $33,886
Injection, iron dextran, 50 mg J1750 Office 46 1,170 $15,755
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 12 93 $13,064
Injection, aprepitant, 1 mg J0185 Office 15 4,290 $5,595

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 56 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Blincyto
$214 — —
BRUKINSA
$193 20 —
XTANDI
$142 24 —
ENHERTU
$139 — —
MONJUVI
$133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 56 with Patron

Records

669 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record